- Home
- EQNR vs SNY Comparison
EQNR vs SNY Comparison
Compare EQNR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EQNR | SNY |
|---|---|---|
| Founded | 1972 | 1994 |
| Country | Norway | France |
| Employees | 24140 | 74846 |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.0B | 101.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EQNR | SNY |
|---|---|---|
| Price | $39.63 | $43.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $37.00 | ★ $58.00 |
| AVG Volume (30 Days) | ★ 3.8M | 2.7M |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | 3.08% | ★ 3.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.35 | $3.49 |
| Revenue Next Year | N/A | $6.10 |
| P/E Ratio | $14.56 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.26 | $42.33 |
| 52 Week High | $43.46 | $53.36 |
Technical Indicators
Market Signals| Indicator | EQNR | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 41.23 |
| Support Level | $23.15 | $43.32 |
| Resistance Level | $41.88 | $48.76 |
| Average True Range (ATR) | 1.00 | 0.64 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 63.18 | 26.32 |
Price Performance
Historical ComparisonAbout EQNR Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2025 (50% liquids) and ended 2025 with 5.2 billion barrels of proven reserves (45% liquids). Operations also include oil refineries and natural gas processing, marketing, and trading. The renewables portfolio includes offshore and onshore wind and solar, with total power generation of 5.65 TWh in 2025.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.